Understanding COVID-19 vaccine responses in the setting of immunotherapy (Sub-study)
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
30 participants needed
1 Location
Brief description of study
This research is a sub-study to the “Understanding influenza vaccine responses in the setting of immunotherapy” protocol (parent study). This sub-study is open to only those participants that have consented to be part of the above parent study.
This study is designed to better understand antibody responses in the setting of PD-1 blockade compared to other anti-cancer therapies in melanoma patients. Identification of impaired vaccine responses would have major implications for vaccination in the setting of immunotherapy and will also elucidate the role of PD-1 signaling in generating an effective antibody-mediated immune response.
Available published data from vaccine trials indicate immunogenicity and serological immunity, but key questions remain about the nature of the cellular immune response underlying antibody responses. Understanding the nature of T cell and B cell responses to the SARS-Cov2 vaccines is of paramount importance to gain a deeper knowledge of immunity to COVID-19 and to improve vaccination strategies in the future.
Detailed description of study
Adult participants with a diagnosis of locally advanced or metastatic melanoma will be recruited at the Melanoma Clinic.
Potential participants will be identified by study personnel in the Perelman Center for Advanced Medicine or Penn Medicine Valley Forge.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Covid-19 vaccination,melanoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844967
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
